Be wary in the post-Roe v Wade world 1 in 17 pts who tried to fill MTX experienced unexpected barriers Most issues with pharmacy seeking to confirm purpose of Rx - doctors should include dx on prescription! #ACRBest Abs#L09 @RheumNow #ACR22 https://t.co/WOWCfOPWUk

FMF should be considered in people with short-lived and red mono-oligoarthritis in the large joints of the lower extremities. Abs 1830 #ACR22 @RheumNow https://t.co/86AJkhd0br https://t.co/KuWuTDhgwj

• Characteristics of Arthritis in Familial Mediterranean Fever Patients - ACR Mee…

Canakinumab provides a significant reduction in disease severity, attack frequency, and acute phase reactant levels in FMF. Abs 1834 #ACR22 @RheumNow https://t.co/3JYDi7eaBU https://t.co/NepMkQniiB

• Canakinumab Treatment in Familial Mediterranean Fever Patients with Colchicine …

ORAL Surveillance update! Composite ischemic CV/HF risk not numerically different w/ tofa vs TNFi. In pts w/ ASCVD hx, MACE endpoints were numerically higher w/ tofa. CV risk was higher w/ tofa 10 mg BID vs TNFi. Check out CIs! Abs L06 #ACR22 @RheumNow https://t.co/XXTsU4el66 https://t.co/WvFqziKVkT

• Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib …

Is there ↑ delay in #Dermatomyositis dx and tx by race? Abstr #1861 showed: Median # of days from Dx → Tx by race: - White: 4 days - Hispanic: 14 days - Black: 21 Whites vs other races: 4 vs 14 days @RheumNow #ACR22 https://t.co/wWgfgtRHa5

#ACR22 Abstr#0996 After #Lupus target is met (LLDAS/DORIS Clinical/Complete Remission), is it safe to further taper steroid/ immunosuppressant? A study in Asia-Pacific reported in stable SLE, tapering increased flares. Best done in sustained complete remission state @RheumNow https://t.co/oa1Os6bARk

IgG4 RD study Abs 1840 at #ACR22 finds “Retroperitoneum and Aorta” and “Head and Neck-Limited” phenotypes more difficult than expected to capture w/ 2019 ACR/EULAR criteria. @RheumNow https://t.co/y045bTWVmC https://t.co/bA8MMiN7hT

• The 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease Perform Low…

🪐COSMOS trial in PsA🪐 #ACR22 @RheumNow Abstract #2110 ⭐️285 pt. failed to respond to TNFi ⭐️Guselkumab 100 mg q8w vs. PBO (crossed over GUS at 16 or 24w) ⭐️response to GUS as early as 8w and did not plateau by 48w ⭐️By 48w, 30-33% pts. achieved min. disease activity

Than et al. Delay in starting MTX by 1 month in RA no impact on 1 year disease activity or structural outcomes. @RheumNow #ACR22 Abstr#1960 https://t.co/Kn2kHlQFpA https://t.co/EyfofVySC9

• Impact of Delaying Initiation of Methotrexate by One Month on the Outcome of RA…

RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its Faculty.

Just so good to see PMR on the plenary stage at #ACR22, after #EULAR2022 too SAPHYR study: sarilumab allows for - a quicker steroid wean & less toxicity - but also far more disease remission, quicker symptom resolution, better quality of life Game-changing. ABST1676 @RheumNow https://t.co/ZVqlMNoniu https://t.co/Fv3VRZrKGe

• https://twitter.com/drdavidliew/status/1533040378386993153

Do you think you need a #steroid sparing Rx in #polymyalgia #rheumatica? +data in #sarilumab w 14 wk ped taper. No diverticulitis, ?Stacking comparator grp to flare as past steroid tapering caused a flare. But that is an unmet need after long pred Rx Abst#1543 #ACR22 @RheumNow https://t.co/Q1bhYs7LEz

Intersting discussion post Plenary this AM - Agree w/RS that we should taper steroid - Is there a disease modifying benefit? I think not - When should this be used? Disagree w/RS, I would not use unless relapsing/refractory and requiring >10mg pred #ACR22 @RheumNow https://t.co/ylGXk2sca7

• https://twitter.com/EBRheum/status/1591864082705129472